This ECI conference focuses on the engineering and pragmatic approaches required to develop, refine, characterize, scale-up, automate, validate, and commercialize processes and assays to manufacture, test, store, and distribute cell-based therapies.
San Diego, CA
15/01/2017 - 8:30 am
19/01/2017 - 5:00 pm
There is tremendous clinical promise for emerging therapies based on administrating cells to patients to treat a diverse assortment of diseases. However, the complexity of cells that affords great therapeutic promise also increases the complexity of their manufacture and testing. Furthermore, there are distinct challenges for the many forms of cell products (e.g., autologous vs. allogeneic, fresh vs. frozen).
The ability to manufacture and perform assays that confirm the quality of cell products will be critical factors in the anticipated success of cell-based therapies. In particular, it is necessary to develop manufacturing processes that are scalable, cost-effective, and reliable, along with measurements of cell characteristics that are pertinent to product quality.
On 17 January 9:25 - 9:45am, Dr Damian Marshall, Head of Analytical Development, will be presenting Novel assays for immunotherapy product characterization and potency measurement. Jahid Hasan will also be presenting a poster titled Development of a cost efficient platform for the industrial manufacturing of pluripotent stem cell derived products for cell therapy: Cell expansion is the starting point.